AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 8708151 — intervention group
Group type: EXPERIMENTAL
Intervention: Intralesional IFN alfa-2b
Number of subjects: 45
Study 8708151 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of intralesional IFN alfa-2a and 2b
Number of subjects: 45
Study 1876419 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypnosis (HA)
Number of subjects: 8
Study 1876419 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture (AA)
Number of subjects: 8
Study 1876419 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 1876419 — intervention group
Group type: COMPARATOR
Intervention: Naloxone
Number of subjects: 8
Study 31410649 — intervention group
Group type: EXPERIMENTAL
Intervention: Kinesiotaping plus exercise program
Number of subjects: 42
Study 31410649 — intervention group
Group type: COMPARATOR
Intervention: Exercise program only
Number of subjects: 42
Study 27862173 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse Navigator Programme
Number of subjects: 120
Study 27862173 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard care)
Number of subjects: 120
Study 25239059 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefozopran
Number of subjects: 376
Study 25239059 — intervention group
Group type: EXPERIMENTAL
Intervention: Meropenem
Number of subjects: 376
Study 25239059 — intervention group
Group type: EXPERIMENTAL
Intervention: Imipenem-cilastatin
Number of subjects: 376
Study 25239059 — intervention group
Group type: COMPARATOR
Intervention: Cefepime
Number of subjects: 376
Study 25239059 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbapenem (Imipenem-cilastatin and Meropenem combined)
Number of subjects: 376
Study 23642508 — intervention group
Group type: EXPERIMENTAL
Intervention: EuroSCORE II (ESII)
Number of subjects: 537
Study 23642508 — intervention group
Group type: COMPARATOR
Intervention: additive EuroSCORE (addES)
Number of subjects: 537
Study 23642508 — intervention group
Group type: COMPARATOR
Intervention: logistic EuroSCORE (logES)
Number of subjects: 537
Study 21562091 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-fat dietary intervention (DM-I)
Number of subjects: 2263
Study 19161542 — intervention group
Group type: EXPERIMENTAL
Intervention: 2000 IU daily of vitamin D(2) for mothers
Number of subjects: 90
Study 19161542 — intervention group
Group type: EXPERIMENTAL
Intervention: 60,000 IU monthly of vitamin D(2) for mothers
Number of subjects: 90
Study 19161542 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 IU daily of vitamin D(2) for infants
Number of subjects: 90
Study 19161542 — intervention group
Group type: EXPERIMENTAL
Intervention: Milk antirachitic activity
Number of subjects: 90
Study 17450047 — intervention group
Group type: EXPERIMENTAL
Intervention: Fast/once daily titration (1.2 mg/kg/day over 3 days)
Number of subjects: 447
Study 17450047 — intervention group
Group type: COMPARATOR
Intervention: Slow/twice daily titration (1.2 mg/kg/day over at least 2 weeks)
Number of subjects: 447
Study 17450047 — intervention group
Group type: COMPARATOR
Intervention: Slow/twice daily titration
Number of subjects: 447
Study 15016780 — intervention group
Group type: EXPERIMENTAL
Intervention: GnRH agonist therapy with 400 mcg buserelin acetate daily followed by 6 mg of oral estradiol valerate starting on menstrual day 1
Number of subjects: 234
Study 15016780 — intervention group
Group type: COMPARATOR
Intervention: No GnRH agonist therapy, starting 6 mg of oral estradiol valerate on day 1 of bleeding
Number of subjects: 234
Study 11206232 — intervention group
Group type: EXPERIMENTAL
Intervention: Formoterol 12 microg twice daily
Number of subjects: 541
Study 11206232 — intervention group
Group type: EXPERIMENTAL
Intervention: Formoterol 24 microg twice daily
Number of subjects: 541
Study 11206232 — intervention group
Group type: EXPERIMENTAL
Intervention: Formoterol (both doses)
Number of subjects: 541
Study 11206232 — intervention group
Group type: COMPARATOR
Intervention: Albuterol 180 microg four times daily
Number of subjects: 541
Study 11206232 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 541
Study 9537731 — intervention group
Group type: EXPERIMENTAL
Intervention: Gauze drain impregnated with chlortetracycline ointment
Number of subjects: 26
Study 9537731 — intervention group
Group type: COMPARATOR
Intervention: No drain treatment (control)
Number of subjects: 26
Study 8079448 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose IVIgG (85.7 +/- 11.6 mg/kg by ultrasound‐estimated fetal weight)
Number of subjects: 20
Study 8079448 — intervention group
Group type: COMPARATOR
Intervention: Intrauterine intravascular red cell transfusions (IUT)
Number of subjects: 20
Study 8079448 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose IVIgG
Number of subjects: 20
Study 2590616 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal metoclopramide (5 mg in 0.5 ml sterile water)
Number of subjects: 0
Study 2590616 — intervention group
Group type: COMPARATOR
Intervention: Oral route (implied control)
Number of subjects: 0
Study 241307 — intervention group
Group type: EXPERIMENTAL
Intervention: Single daily administration of phenothiazine medication
Number of subjects: 24
Study 241307 — intervention group
Group type: COMPARATOR
Intervention: Multiple administration schedule of phenothiazine medication
Number of subjects: 24
Study 31711880 — intervention group
Group type: EXPERIMENTAL
Intervention: Active high-frequency DMPFC-rTMS
Number of subjects: 120
Study 31711880 — intervention group
Group type: EXPERIMENTAL
Intervention: Active low-frequency DMPFC-rTMS
Number of subjects: 120
Study 31711880 — intervention group
Group type: COMPARATOR
Intervention: Sham DMPFC-rTMS
Number of subjects: 120
Study 31329855 — intervention group
Group type: EXPERIMENTAL
Intervention: AKCEA-APOCIII-LRx 10 mg
Number of subjects: 0
Study 31329855 — intervention group
Group type: EXPERIMENTAL
Intervention: AKCEA-APOCIII-LRx 30 mg
Number of subjects: 0
Study 31329855 — intervention group
Group type: EXPERIMENTAL
Intervention: AKCEA-APOCIII-LRx 60 mg
Number of subjects: 0
Study 31329855 — intervention group
Group type: EXPERIMENTAL
Intervention: AKCEA-APOCIII-LRx 90 mg
Number of subjects: 0
Study 31329855 — intervention group
Group type: EXPERIMENTAL
Intervention: AKCEA-APOCIII-LRx 120 mg
Number of subjects: 0
Study 31329855 — intervention group
Group type: EXPERIMENTAL
Intervention: AKCEA-APOCIII-LRx 15 mg weekly for 6 weeks
Number of subjects: 0
Study 31329855 — intervention group
Group type: EXPERIMENTAL
Intervention: AKCEA-APOCIII-LRx 30 mg weekly for 6 weeks
Number of subjects: 0
Study 31329855 — intervention group
Group type: EXPERIMENTAL
Intervention: AKCEA-APOCIII-LRx 60 mg every 4 weeks for 3 months
Number of subjects: 0
Study 31329855 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 31329855 — intervention group
Group type: EXPERIMENTAL
Intervention: AKCEA-APOCIII-LRx
Number of subjects: 0
Study 28038840 — intervention group
Group type: EXPERIMENTAL
Intervention: Telavancin
Number of subjects: 409
Study 26171911 — intervention group
Group type: EXPERIMENTAL
Intervention: Trebananib (15mg/kg, IV QW)
Number of subjects: 32
Study 24029303 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle intervention (exercise training, salt restriction, nutrition advice) for 24 weeks
Number of subjects: 70
Study 24029303 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle intervention
Number of subjects: 70
Study 24029303 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 70
Study 21159452 — intervention group
Group type: EXPERIMENTAL
Intervention: MMT with weekly individual BDRC (n=20)
Number of subjects: 37
Study 21159452 — intervention group
Group type: COMPARATOR
Intervention: Standard MMT (n=17)
Number of subjects: 37
Study 18193489 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium carbonate (MgCO(3))
Number of subjects: 46
Study 18193489 — intervention group
Group type: COMPARATOR
Intervention: Calcium carbonate (CaCO(3))
Number of subjects: 46
Study 16640847 — intervention group
Group type: EXPERIMENTAL
Intervention: DTPw-HB/Hib vaccine (5 microg of PRP), given as a single injection
Number of subjects: 0
Study 16640847 — intervention group
Group type: COMPARATOR
Intervention: Licensed DTPw-HB (Tritanrix) and Hib (Hiberix) vaccines, given as simultaneous concomitant injections
Number of subjects: 0
Study 16640847 — intervention group
Group type: EXPERIMENTAL
Intervention: DTPw-HB/Hib vaccine
Number of subjects: 0
Study 16640847 — intervention group
Group type: COMPARATOR
Intervention: Licensed DTPw-HB and Hib vaccines
Number of subjects: 0
Study 16640847 — intervention group
Group type: EXPERIMENTAL
Intervention: Both vaccination regimens
Number of subjects: 0
Study 12969103 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal midazolam (1 mg) added to 3 ml of 0.5% hyperbaric bupivacaine
Number of subjects: 40
Study 12969103 — intervention group
Group type: COMPARATOR
Intervention: Control group (3 ml of 0.5% hyperbaric bupivacaine alone
Number of subjects: 40
Study 10718796 — intervention group
Group type: EXPERIMENTAL
Intervention: Total fundoplication
Number of subjects: 164
Study 10718796 — intervention group
Group type: EXPERIMENTAL
Intervention: Calibration of the cardia with posterior gastropexy
Number of subjects: 164
Study 10718796 — intervention group
Group type: COMPARATOR
Intervention: Barrett's oesophagus
Number of subjects: 164
Study 10718796 — intervention group
Group type: COMPARATOR
Intervention: Visick I or II
Number of subjects: 164
Study 8808360 — intervention group
Group type: EXPERIMENTAL
Intervention: Discharge instructions with the modular, multidisciplinary pediatric burn discharge book
Number of subjects: 123
Study 8808360 — intervention group
Group type: COMPARATOR
Intervention: Routine discharge teaching without the book
Number of subjects: 123
Study 8808360 — intervention group
Group type: EXPERIMENTAL
Intervention: Discharge instructions with the modular, multidisciplinary pediatric burn discharge book (NAI families)
Number of subjects: 123
Study 8808360 — intervention group
Group type: COMPARATOR
Intervention: Routine teaching (NAI families)
Number of subjects: 123
Study 1345260 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol 50 mg o.d.
Number of subjects: 0
Study 1345260 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril 20 mg o.d.
Number of subjects: 0
Study 1345260 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisinopril
Number of subjects: 0
Study 1345260 — intervention group
Group type: COMPARATOR
Intervention: Self-measurements of blood pressure (self-BP)
Number of subjects: 0
Study 1345260 — intervention group
Group type: COMPARATOR
Intervention: Office blood pressure (office-BP)
Number of subjects: 0
Study 3974160 — intervention group
Group type: EXPERIMENTAL
Intervention: Pindolol eye drops 1%
Number of subjects: 33
Study 3974160 — intervention group
Group type: COMPARATOR
Intervention: Timolol eye drops 0.5%
Number of subjects: 33
Study 29077615 — intervention group
Group type: EXPERIMENTAL
Intervention: Epinephrine 200 µg (high-dose group)
Number of subjects: 68
Study 29077615 — intervention group
Group type: EXPERIMENTAL
Intervention: Epinephrine 100 µg (low-dose group)
Number of subjects: 68
Study 29077615 — intervention group
Group type: COMPARATOR
Intervention: No epinephrine (NE group)
Number of subjects: 68
Study 27837602 — intervention group
Group type: EXPERIMENTAL
Intervention: Multicomponent behavioral intervention administered by lay health workers (5 weekly 90-minute sessions)
Number of subjects: 346
Study 27837602 — intervention group
Group type: EXPERIMENTAL
Intervention: Multicomponent behavioral intervention
Number of subjects: 346
Study 27837602 — intervention group
Group type: COMPARATOR
Intervention: Enhanced usual care
Number of subjects: 346
Study 25103138 — intervention group
Group type: EXPERIMENTAL
Intervention: Maximal isometric hip and thigh strength measurements after 1 week
Number of subjects: 122
Study 25103138 — intervention group
Group type: EXPERIMENTAL
Intervention: Leg extensor power measurements
Number of subjects: 122
Study 25103138 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional performance measures (8-foot Up & Go, stair climbing, chair stand, 6-min walk)
Number of subjects: 122
Study 25103138 — intervention group
Group type: COMPARATOR
Intervention: Quadriceps strength measurements in healthy peers
Number of subjects: 122
Study 22561390 — intervention group
Group type: EXPERIMENTAL
Intervention: Counselor Initiated (proactive) group, receiving 6 counseling sessions and an 8-week supply of NRT
Number of subjects: 1000
Study 22561390 — intervention group
Group type: COMPARATOR
Intervention: Self-Paced (reactive) group, receiving the same counseling sessions and a 2-week supply of NRT
Number of subjects: 1000
Study 20486914 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual immunosuppressive therapy
Number of subjects: 0
Study 20486914 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower blood concentrations of calcineurin inhibitors
Number of subjects: 0
Study 20486914 — intervention group
Group type: EXPERIMENTAL
Intervention: Longer time since transplantation
Number of subjects: 0
Study 20486914 — intervention group
Group type: EXPERIMENTAL
Intervention: Tacrolimus therapy
Number of subjects: 0
Study 20486914 — intervention group
Group type: EXPERIMENTAL
Intervention: Mycophenolate therapy
Number of subjects: 0
Study 20486914 — intervention group
Group type: EXPERIMENTAL
Intervention: Valganciclovir/ganciclovir therapy with lower total intensity of immunosuppressive therapy
Number of subjects: 0
Study 20486914 — intervention group
Group type: EXPERIMENTAL
Intervention: Mycophenolate and tacrolimus therapy
Number of subjects: 0
Study 18608978 — intervention group
Group type: EXPERIMENTAL
Intervention: Instruction set reminder for the Autobiographical Memory Test (AMT)
Number of subjects: 0
Study 18608978 — intervention group
Group type: COMPARATOR
Intervention: Control task's instruction set
Number of subjects: 0
Study 15654774 — intervention group
Group type: COMPARATOR
Intervention: Esomeprazole, Omeprazole, Ranitidine, or Placebo (exact dosages and durations not specified)
Number of subjects: 2674
Study 11916787 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine HCl 2% with epinephrine 1:100,000 via iontophoresis
Number of subjects: 59
Study 11916787 — intervention group
Group type: COMPARATOR
Intervention: Placebo (same formulation without lidocaine) via iontophoresis
Number of subjects: 59
Study 10216810 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine 5 mg once daily for 10 weeks
Number of subjects: 115
Study 10216810 — intervention group
Group type: COMPARATOR
Intervention: Amlodipine 5 mg once daily for 2 weeks, with the option to increase to 10 mg once daily if diastolic blood pressure exceeded 90 mmHg
Number of subjects: 115
Study 8582497 — intervention group
Group type: EXPERIMENTAL
Intervention: sIL-2R in PTL and TL groups (n = 15 and n = 17 respectively)
Number of subjects: 15
Study 8582497 — intervention group
Group type: EXPERIMENTAL
Intervention: sCD8 in PTL and TL groups (n = 15 and n = 17 respectively)
Number of subjects: 15
Study 8582497 — intervention group
Group type: EXPERIMENTAL
Intervention: sCD8 in PTL subgroup with histological evidence of inflammation
Number of subjects: 15
Study 8582497 — intervention group
Group type: COMPARATOR
Intervention: Comparison of PTL and TL groups
Number of subjects: 15
Study 2223679 — intervention group
Group type: EXPERIMENTAL
Intervention: Betamethasone (1.5 mg orally per day from day 259 to day 273, then 1 mg until delivery)
Number of subjects: 28
Study 2223679 — intervention group
Group type: COMPARATOR
Intervention: Non-treatment group
Number of subjects: 28
Study 2223679 — intervention group
Group type: EXPERIMENTAL
Intervention: Betamethasone
Number of subjects: 28
Study 496239 — intervention group
Group type: EXPERIMENTAL
Intervention: Atropine
Number of subjects: 0
Study 496239 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyoscine
Number of subjects: 0
Study 496239 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycopyrronium
Number of subjects: 0
Study 496239 — intervention group
Group type: COMPARATOR
Intervention: Control (no anticholinergic premedication)
Number of subjects: 0
Study 496239 — intervention group
Group type: EXPERIMENTAL
Intervention: Suxamethonium
Number of subjects: 0
Study 30608872 — intervention group
Group type: EXPERIMENTAL
Intervention: Echinacea purpurea (8000 mg·day‐1)
Number of subjects: 24
Study 30608872 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 29285889 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical liposome incorporated clove oil 45%
Number of subjects: 60
Study 29285889 — intervention group
Group type: COMPARATOR
Intervention: 0.9% saline solution (control)
Number of subjects: 60
Study 27473571 — intervention group
Group type: EXPERIMENTAL
Intervention: Asthma self-management model provided by a pharmacist over 4 months
Number of subjects: 119
Study 27473571 — intervention group
Group type: EXPERIMENTAL
Intervention: Asthma self-management model
Number of subjects: 119
Study 25227062 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive verticality analysis and web-based rehabilitation system with face-to-face sessions and home exercises
Number of subjects: 10
Study 22169248 — intervention group
Group type: EXPERIMENTAL
Intervention: Davunetide (AL-108) 5 mg
Number of subjects: 63
Study 22169248 — intervention group
Group type: EXPERIMENTAL
Intervention: Davunetide (AL-108) 30 mg
Number of subjects: 63
Study 22169248 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 63
Study 20086201 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise only (EXO)
Number of subjects: 79
Study 20086201 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet-induced weight loss (DIO)
Number of subjects: 79
Study 20086201 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise and diet-induced weight loss combined (DEX)
Number of subjects: 79
Study 17400675 — intervention group
Group type: EXPERIMENTAL
Intervention: Verbal Training (VT)
Number of subjects: 107
Study 17400675 — intervention group
Group type: EXPERIMENTAL
Intervention: 2Tone Trainer (2T)
Number of subjects: 107
Study 17400675 — intervention group
Group type: COMPARATOR
Intervention: Good Technique (GT)
Number of subjects: 107
Study 15749218 — intervention group
Group type: EXPERIMENTAL
Intervention: Full-thickness skin graft from inner upper arm
Number of subjects: 62
Study 15749218 — intervention group
Group type: COMPARATOR
Intervention: Split-skin graft
Number of subjects: 62
Study 11889309 — intervention group
Group type: EXPERIMENTAL
Intervention: Inspired gas at body temperature and saturated
Number of subjects: 10
Study 11889309 — intervention group
Group type: EXPERIMENTAL
Intervention: Inspired gas conditions of 30 degrees C, 30 mg/L; 34 degrees C, 38 mg/L; 37 degrees C, 44 mg/L; and 40 degrees C, 50 mg/L
Number of subjects: 10
Study 10080336 — intervention group
Group type: EXPERIMENTAL
Intervention: IFN-alpha (1 x 10(6) IU per dose)
Number of subjects: 57
Study 10080336 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-FU (5 mg per dose)
Number of subjects: 57
Study 10080336 — intervention group
Group type: EXPERIMENTAL
Intervention: Alternating IFN-alpha and 5-FU (BOTH)
Number of subjects: 57
Study 8547212 — intervention group
Group type: EXPERIMENTAL
Intervention: Digoxin
Number of subjects: 1731
Study 8547212 — intervention group
Group type: COMPARATOR
Intervention: No Digoxin
Number of subjects: 1731
Study 8547212 — intervention group
Group type: EXPERIMENTAL
Intervention: Digoxin in heart failure patients
Number of subjects: 1731
Study 8547212 — intervention group
Group type: EXPERIMENTAL
Intervention: Digoxin in non-heart failure patients
Number of subjects: 1731
Study 2024225 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticarcillin and clavulanate potassium
Number of subjects: 0
Study 2024225 — intervention group
Group type: COMPARATOR
Intervention: Gentamicin and clindamycin
Number of subjects: 0
Study 7171140 — intervention group
Group type: EXPERIMENTAL
Intervention: Electropharmaceutical anesthesia (EPA)
Number of subjects: 17
Study 7171140 — intervention group
Group type: COMPARATOR
Intervention: Neuroleptanalgesia (NLA)
Number of subjects: 17
Study 31992379 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with depressive disorders
Number of subjects: 192685
Study 31992379 — intervention group
Group type: COMPARATOR
Intervention: Patients without depression
Number of subjects: 192685
Study 30472318 — intervention group
Group type: EXPERIMENTAL
Intervention: FAmily‐CEntered (FACE) ACP intervention (two sessions including goals of care conversation and Five Wishes advance directive)
Number of subjects: 233
Study 30472318 — intervention group
Group type: COMPARATOR
Intervention: Healthy living control (conversations about developmental/relationship history and nutrition)
Number of subjects: 233
Study 30472318 — intervention group
Group type: EXPERIMENTAL
Intervention: FAmily‐CEntered (FACE) ACP intervention among African-Americans
Number of subjects: 233
Study 27805791 — intervention group
Group type: EXPERIMENTAL
Intervention: Collagen mesh‐assisted closure
Number of subjects: 58
Study 27805791 — intervention group
Group type: COMPARATOR
Intervention: Conventional abdominal wound closure
Number of subjects: 58
Study 25576879 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral salmon calcitonin treatment for 2 years
Number of subjects: 2206
Study 25576879 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2206
Study 25252721 — intervention group
Group type: EXPERIMENTAL
Intervention: Compression depth >38 mm
Number of subjects: 9136
Study 25252721 — intervention group
Group type: EXPERIMENTAL
Intervention: Compression depth increment of 5 mm
Number of subjects: 9136
Study 25252721 — intervention group
Group type: EXPERIMENTAL
Intervention: Percentage of minutes in depth range (10% change)
Number of subjects: 9136
Study 25252721 — intervention group
Group type: EXPERIMENTAL
Intervention: Compression depth range 40.3 to 55.3 mm
Number of subjects: 9136
Study 22322513 — intervention group
Group type: EXPERIMENTAL
Intervention: Scaling, root planning, and systemic administration of doxycycline
Number of subjects: 53
Study 22322513 — intervention group
Group type: COMPARATOR
Intervention: Scaling and root planning
Number of subjects: 53
Study 19804842 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential therapy (PPI, amoxicillin followed by PPI, clarithromycin, and imidazole agent)
Number of subjects: 232
Study 19804842 — intervention group
Group type: EXPERIMENTAL
Intervention: Concomitant therapy (PPI, amoxicillin, clarithromycin, and imidazole agent)
Number of subjects: 232
Study 19804842 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential therapy
Number of subjects: 232
Study 19804842 — intervention group
Group type: EXPERIMENTAL
Intervention: Concomitant therapy
Number of subjects: 232
Study 17626987 — intervention group
Group type: EXPERIMENTAL
Intervention: Crystacide (hydrogen peroxide cream) applied onto the skin for 10 days
Number of subjects: 32
Study 17626987 — intervention group
Group type: COMPARATOR
Intervention: Control group (treated without Crystacide)
Number of subjects: 32
Study 16131287 — intervention group
Group type: EXPERIMENTAL
Intervention: Lavandula augustifolia (lavender)
Number of subjects: 10